ATL-2502
Identification
- Generic Name
- ATL-2502
- DrugBank Accession Number
- DB05340
- Background
ATL-2502(Colal-Pred) is an old drug (prednisolone metasulphobenzoate, a steroid) with a new delivery system that releases the medication only in the colon. Releasing the drug directly into the colon reduces the potential for significant side effects often experienced with steroid drugs. Colal-Pred is being studied for use in ulcerative colitis.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 566.595
Monoisotopic: 566.158647955 - Chemical Formula
- C28H31NaO9S
- Synonyms
- Not Available
Pharmacology
- Indication
Investigated for use/treatment in inflammatory bowel disease and ulcerative colitis.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
ATL-2502 is the combination of Alizyme's proprietary colonic drug delivery system, colal, and prednisolone metasulfobenzoate sodium ("PMSBS"), an approved steroid in Europe. colal-PRED has a starch coating that is only broken down in the gut by bacteria occurring in the colon. This leads to topical delivery of PMSBS to the colon rather than systemic delivery with the objective of providing efficacy, but without the side effects of steroids; however, the efficacy and safety of colal-PRED must be shown in well-controlled, prospective clinical trials and approved by the FDA.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- International/Other Brands
- Colal-Pred
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image KORTISETIN GÖZ POMADI, 2.5 G ATL-2502 (75 mg) + Chlorhexidine gluconate (300 mg) Ointment Ophthalmic HÜSNÜ ARSAN İLAÇLARI A.Ş. 2020-08-14 2020-01-27 Turkey KORTISETIN GÖZ POMADI, 5 G ATL-2502 (150 mg) + Chlorhexidine gluconate (600 mg) Ointment Ophthalmic HÜSNÜ ARSAN İLAÇLARI A.Ş. 2020-08-14 2020-01-27 Turkey
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- D345THM53T
- CAS number
- Not Available
- InChI Key
- RWFZSORKWFPGNE-UHFFFAOYSA-M
- InChI
- InChI=1S/C28H32O9S.Na/c1-26-10-8-18(29)13-17(26)6-7-20-21-9-11-28(33,27(21,2)14-22(30)24(20)26)23(31)15-37-25(32)16-4-3-5-19(12-16)38(34,35)36;/h3-5,8,10,12-13,20-22,24,30,33H,6-7,9,11,14-15H2,1-2H3,(H,34,35,36);/q;+1/p-1
- IUPAC Name
- sodium 3-[(2-{1,10-dihydroxy-9a,11a-dimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl}-2-oxoethoxy)carbonyl]benzene-1-sulfonate
- SMILES
- [Na+].CC12CC(O)C3C(CCC4=CC(=O)C=CC34C)C1CCC2(O)C(=O)COC(=O)C1=CC(=CC=C1)S([O-])(=O)=O
References
- General References
- Hanauer SB, Sparrow M: COLAL-PRED Alizyme. Curr Opin Investig Drugs. 2004 Nov;5(11):1192-7. [Article]
- External Links
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment Ulcerative Colitis 1 2 Completed Treatment Ulcerative Colitis 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Ointment Ophthalmic - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0249 mg/mL ALOGPS logP 2.5 ALOGPS logP 0.81 Chemaxon logS -4.4 ALOGPS pKa (Strongest Acidic) -2.5 Chemaxon pKa (Strongest Basic) -2.9 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 8 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 158.1 Å2 Chemaxon Rotatable Bond Count 6 Chemaxon Refractivity 137.82 m3·mol-1 Chemaxon Polarizability 55.75 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.8897 Blood Brain Barrier + 0.9225 Caco-2 permeable - 0.6316 P-glycoprotein substrate Substrate 0.678 P-glycoprotein inhibitor I Non-inhibitor 0.5478 P-glycoprotein inhibitor II Non-inhibitor 0.7755 Renal organic cation transporter Non-inhibitor 0.7904 CYP450 2C9 substrate Non-substrate 0.8247 CYP450 2D6 substrate Non-substrate 0.8165 CYP450 3A4 substrate Substrate 0.6485 CYP450 1A2 substrate Non-inhibitor 0.7743 CYP450 2C9 inhibitor Non-inhibitor 0.7888 CYP450 2D6 inhibitor Non-inhibitor 0.8678 CYP450 2C19 inhibitor Non-inhibitor 0.7366 CYP450 3A4 inhibitor Non-inhibitor 0.8153 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.7574 Ames test Non AMES toxic 0.578 Carcinogenicity Non-carcinogens 0.6565 Biodegradation Not ready biodegradable 0.6566 Rat acute toxicity 2.4859 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.863 hERG inhibition (predictor II) Non-inhibitor 0.5656
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 225.2097 predictedDeepCCS 1.0 (2019) [M+H]+ 227.60526 predictedDeepCCS 1.0 (2019) [M+Na]+ 234.06264 predictedDeepCCS 1.0 (2019)
Drug created at November 18, 2007 18:24 / Updated at June 12, 2020 16:52